These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15882282)

  • 1. The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men.
    Rule AD; Jacobson DJ; Roberts RO; Girman CJ; McGree ME; Lieber MM; Jacobsen SJ
    Kidney Int; 2005 Jun; 67(6):2376-82. PubMed ID: 15882282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
    Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
    Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status.
    Jacobsen SJ; Jacobson DJ; Girman CJ; Roberts RO; Rhodes T; Guess HA; Lieber MM
    J Urol; 1999 Oct; 162(4):1301-6. PubMed ID: 10492184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Hong SK; Lee ST; Jeong SJ; Byun SS; Hong YK; Park DS; Hong JY; Son JH; Kim C; Jang SH; Lee SE
    BJU Int; 2010 May; 105(10):1424-8. PubMed ID: 19874305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
    Corica FA; Jacobsen SJ; King BF; Bostwick DG; Jacobson DJ; Girman CJ; Lieber MM
    J Urol; 1999 Mar; 161(3):831-4. PubMed ID: 10022695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota.
    Burke JP; Jacobson DJ; McGree ME; Roberts RO; Girman CJ; Lieber MM; Jacobsen SJ
    Urology; 2006 Jan; 67(1):22-5. PubMed ID: 16413325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of high bladder neck elevation with urodynamic bladder outlet obstruction in patients with lower urinary tract symptoms and benign prostatic hyperplasia.
    Kang M; Kim M; Choo MS; Bae J; Ku JH; Yoo C; Oh SJ
    Urology; 2014 Dec; 84(6):1461-6. PubMed ID: 25432841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.
    Oelke M; Baard J; Wijkstra H; de la Rosette JJ; Jonas U; Höfner K
    Eur Urol; 2008 Aug; 54(2):419-26. PubMed ID: 18325657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms.
    Kwon H; Kang HC; Lee JH
    Urology; 2013 Jun; 81(6):1325-9. PubMed ID: 23602796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community.
    Roberts RO; Lieber MM; Jacobson DJ; Girman CJ; Jacobsen SJ
    Mayo Clin Proc; 2005 Jun; 80(6):759-64. PubMed ID: 15948299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ and CD8+ T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia.
    Lamb AD; Qadan M; Roberts S; Timlin H; Vowler SL; Campbell FM; Grigor K; Bartlett JM; McNeill SA
    BJU Int; 2011 Jul; 108(2 Pt 2):E43-50. PubMed ID: 21457430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
    Fukuta F; Masumori N; Mori M; Tsukamoto T
    Int J Urol; 2013 Jan; 20(1):100-6. PubMed ID: 23106204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the clinical value of a simple flowmeter in the management of male lower urinary tract symptoms.
    Chan CK; Yip SK; Wu IP; Li ML; Chan NH
    BJU Int; 2012 Jun; 109(11):1690-6. PubMed ID: 21933332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
    Parsons JK
    J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
    S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
    Tsukamoto T; Masumori N; Rahman M; Crane MM
    Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of lower urinary tract symptom/benign prostatic hyperplasia measures with international index of erectile function 5 in middle-aged policemen of Korea and the role of metabolic syndrome and testosterone in their relationship.
    Lee JH; Kwon H; Park YW
    Urology; 2013 Nov; 82(5):1008-12. PubMed ID: 24041675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.